FDA Approves Travere's FSGS Drug Despite Lack of Kidney Function Improvement

In a notable regulatory decision, the FDA has approved Travere Therapeutics' drug for the rare kidney disease focal segmental glomerulosclerosis (FSGS), even though the treatment did not demonstrate an improvement in kidney function in its pivotal trial. This approval, for the drug sparsentan (branded as Filspari), marks the first-ever therapy specifically for FSGS, a condition where scar tissue forms in the kidneys' filtering units, leading to organ failure. The move represents a significant application of regulatory flexibility, contrasting sharply with recent high-profile FDA rejections of other rare disease treatments.

The approval was granted under the agency's accelerated pathway, which allows for clearance based on a surrogate endpoint—in this case, a reduction in proteinuria, or protein in the urine—that is reasonably likely to predict clinical benefit. The drug met this surrogate goal, showing a greater reduction in proteinuria compared to an active comparator. However, the core measure of kidney health, the estimated glomerular filtration rate (eGFR), did not show a statistically significant improvement over the study period. This disconnect between the surrogate marker and the ultimate clinical outcome of preserving kidney function places the decision under immediate scrutiny.

The action signals the FDA's willingness to exercise discretion for severe, unmet medical needs, but it also raises critical questions for physicians, patients, and payers. Doctors must now weigh the drug's proteinuria benefit against the lack of proven functional improvement when making treatment decisions. The approval pressures insurers to cover a high-cost therapy with an uncertain long-term impact on delaying kidney failure. For Travere, the green light provides a major commercial opportunity in a desperate patient population, yet it also ensures that the drug and the regulatory rationale behind its approval will remain under a microscope as real-world evidence accumulates.